305 related articles for article (PubMed ID: 22549934)
1. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
[TBL] [Abstract][Full Text] [Related]
2. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.
Hou P; Liu D; Xing M
Endocr Relat Cancer; 2011 Dec; 18(6):687-97. PubMed ID: 21937738
[TBL] [Abstract][Full Text] [Related]
4. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.
Guerra A; Sapio MR; Marotta V; Campanile E; Rossi S; Forno I; Fugazzola L; Budillon A; Moccia T; Fenzi G; Vitale M
J Clin Endocrinol Metab; 2012 Feb; 97(2):517-24. PubMed ID: 22170714
[TBL] [Abstract][Full Text] [Related]
5. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
6. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
[TBL] [Abstract][Full Text] [Related]
7. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
[TBL] [Abstract][Full Text] [Related]
9. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
10. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
12. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in
Pappa T; Ahmadi S; Marqusee E; Johnson HL; Nehs MA; Cho NL; Barletta JA; Lorch JH; Doherty GM; Lindeman NI; Alexander EK; Landa I
Clin Cancer Res; 2021 Aug; 27(15):4256-4264. PubMed ID: 34088725
[TBL] [Abstract][Full Text] [Related]
14. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
15. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
16. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
17. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
[TBL] [Abstract][Full Text] [Related]
18. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
20. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
